Pfizer CDR CAD Hedged (PFE) Cours

U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

BRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients with metastatic...

Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EST on Tuesday, February 4, 2025. The...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance

Full-Year 2025 Revenue Guidance(1) Range of $61.0 to $64.0 Billion Full-Year 2025 Adjusted(2) Diluted EPS Guidance Range of $2.80 to $3.00 Expect Full-Year 2025 Adjusted(2) Diluted EPS...

Pfizer Declares First-Quarter 2025 Dividend

Board of Directors approves increase in quarterly cash dividend to $0.43 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash...

Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer

IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy Pfizer Inc...

Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:30 a.m. EST on Tuesday, December 17, 2024. The...

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

– Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6...